HK1026366A1 - Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying - Google Patents

Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying

Info

Publication number
HK1026366A1
HK1026366A1 HK00105598A HK00105598A HK1026366A1 HK 1026366 A1 HK1026366 A1 HK 1026366A1 HK 00105598 A HK00105598 A HK 00105598A HK 00105598 A HK00105598 A HK 00105598A HK 1026366 A1 HK1026366 A1 HK 1026366A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
freeze drying
nucleotide analogue
analogue suitable
nucleotide
Prior art date
Application number
HK00105598A
Other languages
English (en)
Inventor
Chris Bland
Gerald Steele
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of HK1026366A1 publication Critical patent/HK1026366A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK00105598A 1996-12-20 2000-09-05 Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying HK1026366A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation
PCT/SE1997/002068 WO1998028009A1 (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying

Publications (1)

Publication Number Publication Date
HK1026366A1 true HK1026366A1 (en) 2000-12-15

Family

ID=20405148

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00105598A HK1026366A1 (en) 1996-12-20 2000-09-05 Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying

Country Status (36)

Country Link
US (1) US6114313A (xx)
EP (1) EP1007094B1 (xx)
JP (1) JP4488538B2 (xx)
KR (1) KR100552880B1 (xx)
CN (1) CN1121875C (xx)
AR (1) AR010377A1 (xx)
AT (1) ATE221787T1 (xx)
AU (1) AU758857B2 (xx)
BR (1) BR9713974B1 (xx)
CA (1) CA2275153C (xx)
CZ (1) CZ300635B6 (xx)
DE (1) DE69714616T2 (xx)
DK (1) DK1007094T3 (xx)
EE (1) EE03857B1 (xx)
ES (1) ES2182133T3 (xx)
FR (1) FR15C0060I2 (xx)
HK (1) HK1026366A1 (xx)
HU (1) HU226616B1 (xx)
ID (1) ID21635A (xx)
IL (1) IL130449A0 (xx)
IS (1) IS1897B (xx)
MY (1) MY121982A (xx)
NO (1) NO327142B1 (xx)
NZ (1) NZ336027A (xx)
PL (1) PL190493B1 (xx)
PT (1) PT1007094E (xx)
RU (1) RU2205012C2 (xx)
SA (1) SA97180719B1 (xx)
SE (1) SE9604795D0 (xx)
SI (1) SI1007094T1 (xx)
SK (1) SK283137B6 (xx)
TR (1) TR199901412T2 (xx)
TW (1) TW522015B (xx)
UA (1) UA66779C2 (xx)
WO (1) WO1998028009A1 (xx)
ZA (1) ZA9711055B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EA028885B1 (ru) 2009-11-11 2018-01-31 Чиези Фармачеутичи С.П.А. Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты)
CN103582480B (zh) 2011-02-09 2016-03-16 医药公司 治疗肺高压的方法
WO2014143107A1 (en) 2013-03-09 2014-09-18 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
US9295687B1 (en) * 2015-01-14 2016-03-29 The Medicines Company Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
CA3060345A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (xx) * 1973-05-17 1981-09-03
JPH01228915A (ja) * 1988-03-09 1989-09-12 Dai Ichi Seiyaku Co Ltd Atp凍結乾燥製剤
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
CZ281415B6 (cs) * 1989-11-09 1996-09-11 Masarykova Nemocnice S Poliklinikou Iii. Typu Způsob přípravy přenosového faktoru z buffy coatu savčí krve
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition

Also Published As

Publication number Publication date
AU5351598A (en) 1998-07-17
HU226616B1 (en) 2009-04-28
CN1121875C (zh) 2003-09-24
JP2001507022A (ja) 2001-05-29
ATE221787T1 (de) 2002-08-15
MY121982A (en) 2006-03-31
NO993067D0 (no) 1999-06-21
CN1240362A (zh) 2000-01-05
JP4488538B2 (ja) 2010-06-23
HUP0000572A3 (en) 2002-10-28
EP1007094A1 (en) 2000-06-14
BR9713974B1 (pt) 2010-02-23
SA97180719B1 (ar) 2006-05-13
UA66779C2 (uk) 2004-06-15
TW522015B (en) 2003-03-01
IS5064A (is) 1999-06-03
PT1007094E (pt) 2002-12-31
KR20000069598A (ko) 2000-11-25
EE9900260A (et) 2000-02-15
TR199901412T2 (xx) 1999-08-23
WO1998028009A1 (en) 1998-07-02
FR15C0060I2 (fr) 2016-04-22
IS1897B (is) 2003-10-20
DE69714616D1 (de) 2002-09-12
CA2275153A1 (en) 1998-07-02
NO327142B1 (no) 2009-05-04
EE03857B1 (et) 2002-10-15
ID21635A (id) 1999-07-08
ES2182133T3 (es) 2003-03-01
FR15C0060I1 (xx) 2015-10-23
SI1007094T1 (en) 2003-02-28
RU2205012C2 (ru) 2003-05-27
KR100552880B1 (ko) 2006-02-20
SK76499A3 (en) 1999-11-08
SK283137B6 (sk) 2003-03-04
AR010377A1 (es) 2000-06-07
IL130449A0 (en) 2000-06-01
CZ220199A3 (cs) 1999-11-17
BR9713974A (pt) 2000-04-11
CA2275153C (en) 2008-03-25
US6114313A (en) 2000-09-05
DK1007094T3 (da) 2002-10-28
AU758857B2 (en) 2003-04-03
EP1007094B1 (en) 2002-08-07
PL190493B1 (pl) 2005-12-30
PL334006A1 (en) 2000-01-31
ZA9711055B (en) 1998-07-08
SE9604795D0 (sv) 1996-12-20
NZ336027A (en) 2001-03-30
CZ300635B6 (cs) 2009-07-08
HUP0000572A2 (hu) 2001-05-28
DE69714616T2 (de) 2003-04-03
NO993067L (no) 1999-08-09

Similar Documents

Publication Publication Date Title
HK1046357A1 (en) Nucleodide analog compositions
EG24118A (en) Pharmaceutical compositions
GB9727053D0 (en) Pharmaceutical compositions
CY2569B1 (en) Pharmaceutical compositions
HK1026366A1 (en) Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying
GB9616672D0 (en) Pharmaceutical compositions
ZA9710006B (en) Novel pharmaceutical compositions
GB9610359D0 (en) Pharmaceutical compositions
GB9723985D0 (en) Pharmaceutical compositions
GB9622681D0 (en) Pharmaceutical compositions
GB9726735D0 (en) Pharmaceutical compositions
GB9606429D0 (en) Pharmaceutical compositions
SI0996430T1 (en) Nucleotide analog compositions
GB9613457D0 (en) Pharmaceutical compositions
GB9618376D0 (en) Pharmaceutical compositions
GB9623962D0 (en) Pharmaceutical composition
GB9610136D0 (en) Pharmaceutical compositions
SI0941095T1 (en) Improved pharmaceutical compositions
GB9606586D0 (en) Pharmaceutical compositions
GB9603942D0 (en) Pharmaceutical compositions
GB9623225D0 (en) Novel pharmaceutical compositions
GB9611530D0 (en) Pharmaceutical composition
GB9620048D0 (en) Pharmaceutical composition
GB9615627D0 (en) Pharmaceutical composition
GB9626185D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20171210